← Alpha Tau Medical Ltd. (DRTS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Alpha Tau Medical Ltd. (DRTS)
Surgical & Medical Instruments & Apparatus · market cap $1.3B · as of 2026-07-20
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-19 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Alpha Tau Medical Ltd. (DRTS) is a medical device/oncology company with approximately 125 employees and a market cap of ~$906M at ~$13.55/share. Its pipeline spans three assets across oncology indications: AZD3759 (Phase 3, NSCLC), MTL-CEBPA (Phase 2, HCC), and ZN-c5 (Phase 2, breast cancer). The nearest disclosed catalyst is an earnings release on 2026-08-10.
The catalyst path
- 2026-11-19 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| MTL-CEBPA | Phase 2 | Hepatocellular Carcinoma |
| AZD3759 | Phase 3 | Non-small Cell Lung Cancer |
| ZN-c5 | Phase 2 | Breast Cancer |
Price & technical context
3-month
+9.7%
6-month
+109.7%
12-month
+221.7%
52-wk range
$3.47–$15.50
vs 50-day MA
+3.0%
vs 200-day MA
+48.7%
Realized vol
75.4%
Max drawdown
-41.7%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for DRTS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.